JAK2 and leukemia: For example, cells carrying mutations exclusively in JAK2 specifically upregulated B4GALT1 (Figure 5B), which is associated with acquisition of drug resistance in leukemia (Zhou et al., 2013), and cells with mutations in epigenetic modifiers specifically upregulated PITX1, which has been previously implicated in leukemogenesis (Nagel et al., 2011).